| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 23015 |
| Drug | Ivosidenib |
| Brand | Tibsovo® |
| Indication | To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 08/03/2023 |
| Rapid review completed | 17/04/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/06/2023 |
